Cardiovascular
Application of Enzyme-Linked Immunosorbent Assay (ELISA) in Cardiovascular Research
The cardiovascular system consists of the heart and blood vessels. The atria collect blood into the heart, and the ventricles eject blood out of the heart. Both the inlet and the outlet of the ventricle have valves to ensure one-way blood flow. The human body has different metabolic levels of various organs and tissues under different physiological conditions and different needs for blood flow. Cardiovascular activity can change the cardiac output and peripheral resistance under the mediation of the body's nerves and body fluids, and coordinate the distribution of blood flow between various organs and tissues to meet the needs of various organs and tissues for blood flow. The normal physiological functions of the cardiovascular system are essential to the health of the body. The survey found that cardiovascular disease has become one of the leading causes of death worldwide. It is estimated that 17.9 million people died of cardiovascular disease in 2019, accounting for 32% of global deaths. Hypertension, atherosclerosis, coronary heart disease, etc. are the most common cardiovascular diseases, and ELISA can be widely used in the detection of these cardiovascular diseases through test indicators.
Common Targets in Cardiovascular Research
Adiponectin (ADP)
Apolipoprotein B
Angiotensinogen
Apolipoprotein A1
Cystatin C
Endothelin 2
Plasminogen
Resistin
Vasohibin 1
von Willebrand Factor
Thrombopoietin
Troponin T Type 2
Advantages of ELISA in Cardiovascular Research
- High-throughput screening of samples
- Can detect cardiovascular diseases more conveniently and quickly
- Cardiovascular diseases can be diagnosed early by detecting indicators
Common Targets Detected by ELISA in Cardiovascular Research
Apolipoprotein B
Apolipoprotein B (Apo B) is a protein in plasma lipoproteins. Its basic function is to carry lipids and has important physiological functions in lipoprotein metabolism. Apo B exists on the surface of low-density lipoproteins and is the main structural component of atherosclerotic lipoproteins. Each lipoprotein contains an Apo B molecule. Apo B is mainly used to explain the relationship between lipoprotein lipids and the risk of coronary heart disease and stroke.
Angiotensinogen
Angiotensinogen (AGT), encoded by the AGT gene, is a rate-limiting substrate of the renin-angiotensin system (RAS). AGT can be catalyzed by reninase to produce angiotensin I (ANGI). ANG I is catalyzed by angiotensin-converting enzyme (ACE) to produce ANG II, thereby regulating blood pressure. AGT plays a role in heart failure, hypertension, and atherosclerosis. Early detection of the disease can be done by detecting the level of AGT.
von Willebrand Factor
Von Willebrand Factor (vWF) can bind to collagen fibers and platelets at the same time to promote hemostasis when a blood vessel rupture. Clinical testing found that vWF levels in patients with acute coronary syndrome and acute stroke were significantly increased. Routine detection of vWF activity in patients with vascular disease may have important clinical significance as an indicator of endothelial dysfunction.
Creative Diagnostics has been committed to the application of ELISA in the cardiovascular field. Relying on strong R&D capabilities and advanced technology, we produce a variety of ELISA kits products for cardiovascular research, and we provide high-quality customized ELISA kits services, believable ELISA testing services, and professional ELISA development services related to cardiovascular research according to your needs. If you want more information, please be at liberty to contact us.
References
- Benn, M. Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. Atherosclerosis. 2009, 206(1): 17-30.
- Caulfield, M.; et al. Angiotensinogen in human essential hypertension. Hypertension. 1996, 28(6): 1123-1125.
- Lenting, P.J.; et al. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015, 125(13): 2019-2028.
